12 results about "Increased iron" patented technology

The invention relates to application of a ventral hippocampal region transferrin receptor 1 inhibitor in preparation of a medicine for preventing and / or treating anxiety disorder, and belongs to the technical field of biological medicine. The application of the inhibitor for interfering with the animal brain ventral hippocampal region transferrin receptor 1 (TfR1) in the drugs for preventing and / or treating anxiety is discovered and proposed for the first time. Animal experiments prove that anxiety disorder caused by social isolation stress is closely related to TfR1 in a brain abdominal side hippocampus area of an animal, and when the animal shows anxiety symptom, the expression level of TfR1 is improved, so that the iron concentration in the brain abdominal side hippocampus area is improved to cause iron disorder. On the basis of the research, an inhibitor for interfering with the TfR1 in the belly hippocampus area of the brain of the animal is injected into an anxiety model animal, social isolation treatment is continued, the anxiety behavior of the animal in a social isolation treatment group is improved, and the effect of treating the anxiety is achieved.

The present disclosure provides compositions and methods for increasing disease resistance in plants, for example by increasing IRON MAN (IMA) expression and / or activity, reducing BRUTUS-LIKE E3 ligase (BTSL) expression and / or activity, or both.

The invention relates to novel compounds of the general formula (I-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and / or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders leading to increased iron levels or increased iron absorption, and / or iron overload.

The invention discloses a nano-composite for near-infrared induced explosive ferroptosis and a preparation method and application thereof.The nano-composite is prepared from nano-particles loaded with a ferroptosis inducer and iron-doped dopamine and targeting ligands modified on the surfaces of the nano-particles, the nano-particles take manganese dioxide of a hollow mesoporous structure as a carrier, the ferroptosis inducer is loaded in the hollow mesopores, and the iron-doped dopamine is assembled on the surface of the carrier. Dual regulation and control of effective degradation of endogenous GSH and specific improvement of ROS level in tumor cells are realized through a specific nano composite material and a unique structure, and ferroptosis is increased in combination with a photothermal effect so as to inhibit tumor growth.

Methods of administering ferric citrate to reduce and / or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration), increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron, reduce the need for erythropoiesis-stimulating agents (ESAs), and / or reduce mortality and morbidity related to adverse cardiac events in chronic kidney disease patients, are disclosed.

The present invention relates to a novel process for the preparation of compounds of formula (I) and pharmaceutically acceptable salts thereof, which are suitable for use as drugs for the prevention and / or treatment of diseases caused by hepcidin deficiency or iron metabolism disorders leading to increased iron levels or increased iron absorption, including iron overload, thalassemia, sickle cell disease and hemochromatosis.

The invention relates to a novel compound of the general formula (IA) as defined in the application and a pharmaceutical composition comprising the compound for use as a medicament, in particular for use as a ferroportin inhibitor, more particularly for use in the prophylaxis or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders leading to increased iron levels or increased iron absorption or iron overload.

The invention relates to a new process for preparing compounds of the formula (I) and pharmaceutically acceptable salts thereof, which act as ferroportin inhibitors being suitable for the use as medicaments in the prophylaxis and / or treatment of diseases caused by a lack of hepcidin or of iron metabolism disorders leading to increased iron levels or increased iron absorption, including iron overload, thalassemia, sickle cell disease and hemochromatosis.

The invention relates to a new process for preparing compounds of the formula (I)and pharmaceutically acceptable salts thereof, which act as ferroportin inhibitors being suitable for the use as medicaments in the prophylaxis and / or treatment of diseases caused by a lack of hepcidin or of iron metabolism disorders leading to increased iron levels or increased iron absorption, including iron overload, thalassemia, sickle cell disease and hemochromatosis.

The present invention relates to novel compounds of general formula (I-A) as defined in the present application and pharmaceutical compositions comprising them and their use as medicaments, in particular as inhibitors of iron transporters, more particularly for the prevention and / or treatment of diseases caused by hepcidin deficiency or iron metabolism disorders leading to elevated iron levels, increased iron absorption and / or iron overload. # imgabs0 #

Use of artesunate in the preparation of a medicament for preventing and treating anemia. In vitro experiments have shown that artesunate can enhance the iron transport function of the DMT1 protein to increase iron ion uptake. In addition, animal experiments have demonstrated that artesunate can significantly improve anemia symptoms in mice with iron-deficiency anemia, effectively restore anemia-related indicators, and even restore the iron content in red blood cells and the liver to a healthy level.

The present invention relates to novel compounds of general formula (IA) as defined in the present application and pharmaceutical compositions comprising them and their use as medicaments, in particular for use as ferroportin inhibitors, more particularly for use in the prevention and / or treatment of diseases caused by a lack of hepcidin or disorders of iron metabolism leading to elevated iron levels or increased iron absorption and / or iron overload. JPEG2025535398000130.jpg36129